Evolv Technologies Holdings, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Net Loss per Share (Tables)

Net Loss per Share (Tables)

3 Months Ended

Mar. 31, 2022

Net Loss per Share

Schedule of basic and diluted net loss per share attributable to common stockholders


		Three Months Ended March 31,
		2022			2021
Numerator:
Net loss – basic and diluted		$	(14,551)		$	(13,755)

Denominator:
Weighted average common shares outstanding — basic and diluted			142,878,406			10,443,323
Net loss - basic and diluted		$	(0.10)		$	(1.32)

Schedule of potential common shares excluded from the computation of diluted net loss per share


		Three Months Ended March 31,
		2022		2021
Options issued and outstanding		21,964,309		23,651,872
Public Warrants to purchase common stock		14,324,993		—
Convertible preferred stock (as converted to common stock)		—		80,833,007
Warrants to purchase preferred stock (as converted to warrants to purchase common stock)		—		1,014,963
Warrants to purchase common stock		—		922,297
Warrants to purchase common stock (Finback)**		2,552,913		2,552,913
Unvested restricted stock units		6,251,002		289,047
Unvested performance stock units		934,000		—
Earn-out shares**		15,000,000		—
Contingently issuable common stock**		1,897,500		—
Convertible notes (as converted to common stock)*		—		4,101,960
		62,924,717		113,366,059